AR035819A1 - 2-(amino sustituido)-benzoxazol sulfonamidas, inhibidoras de la proteasa del hiv, composiciones farmaceuticas que comprenden dichos compuestos, metodo in vitro para inhibir la replicacion retroviral y uso de dichos compuestos en la fabricacion de medicamentos - Google Patents
2-(amino sustituido)-benzoxazol sulfonamidas, inhibidoras de la proteasa del hiv, composiciones farmaceuticas que comprenden dichos compuestos, metodo in vitro para inhibir la replicacion retroviral y uso de dichos compuestos en la fabricacion de medicamentosInfo
- Publication number
- AR035819A1 AR035819A1 ARP020101301A ARP020101301A AR035819A1 AR 035819 A1 AR035819 A1 AR 035819A1 AR P020101301 A ARP020101301 A AR P020101301A AR P020101301 A ARP020101301 A AR P020101301A AR 035819 A1 AR035819 A1 AR 035819A1
- Authority
- AR
- Argentina
- Prior art keywords
- 4alkyl
- het2
- alkyl
- het1
- aryl
- Prior art date
Links
- -1 AMINO Chemical class 0.000 title abstract 11
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000338 in vitro Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000010076 replication Effects 0.000 title abstract 2
- 230000001177 retroviral effect Effects 0.000 title abstract 2
- 239000004030 hiv protease inhibitor Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 15
- 125000003118 aryl group Chemical group 0.000 abstract 15
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000003277 amino group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 108010010369 HIV Protease Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 abstract 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 abstract 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
2-(Amino sustituido)-benzoxazol sulfonamidas, inhibidoras de amplio espectro de la proteasa del HIV, que tienen la fórmula (1), sus N-óxidos, sales, formas estereoisoméricas, mezclas racémicas, prodrogas, ésteres, metabolitos, en donde: R1 y R8 son cada uno de ellos e independientemente entre sí, hidrógeno, alquilo de C1-6, alquenilo de C2-6, aril C1-6alquilo, C3-7cicloalquilo, C3-7cicloalquilC1-6alquilo, arilo, Het1, Het1C1-6alquilo, Het2, Het2C1-6alquilo; R1 también puede ser un radical de la fórmula (2) en la cual: R9, R10a y R10b, son cada uno de ellos e independientemente entre sí, hidrógeno, C1-4alquiloxicarbonilo, carboxilo, aminocarbonilo, mono- o di(C1-4alquil)carbonilo, C3-7cicloalquilo, C2-6alquenilo, C2-6alquinilo o alquilo de C1-4 opcionalmente sustituido con arilo, Het1, Het2, C3-7 cicloalquilo, C1-4 alquiloxicarbonilo, carboxilo, aminocarbonilo, mono- o di(C1-4alquil)aminocarbonilo, aminosulfonilo, C1-4alquilS(O)t, hidroxi, ciano, halógeno o amino opcionalmente mono- o di sustituido, estando los sustituyentes, cada uno de ellos e independientemente entre sí, seleccionados de entre el grupo consistente en alquilo de C1-4, arilo, arilC1-4alquilo, C3-7cicloalquilo, C3-7cicloalquilC1-4alquilo, Het1, Het2, Het1C1-4alquilo y Het2C1-4alquilo; con lo cual R9 y R10a y los átomos de carbono a los cuales están fijados pueden también formar un radical C3-7cicloalquilo; cuando L es -O-C1-6 alcanodiil-C(=O)- o -NR8-C1-6alcanodiil-C-(=O)-, entonces R9 también puede ser oxo; R11a es hidrógeno, C2-6alquenilo, C2-6alquinilo, C3-7cicloalquilo, arilo, aminocarbonilo opcionalmente mono o di sustituido, aminoC1-4carboniloxi opcionalmente mono- o di-sustituido, C1-4alquiloxicarbonilo, ariloxicarbonilo, Het1 oxicarbonilo, Het2 oxicarbonilo, ariloxicarbonilC1-4alquilo, arilC1-4 alquiloxicarbonilo, C1-4alquilcarbonilo, C3-7cicloalquilcarbonilo, C3-7 cicloalquilC1-4alquiloxicarbonilo, C3-7cicloalquilcarboniloxi, carboxiC1-4 alquilcarboniloxi, C1-4alquilcarboniloxi, arilC1-4alquilcarboniloxi, ariloxicarboniloxi, Het1 carbonilo, Het1 carboniloxi, Het1 C1-4alquiloxicarbonilo, Het2 carboniloxi, Het2-C1-4alquilcarboniloxi, Het2C1-4alquiloxicarboniloxi, o C1-4 alquilo opcionalmente sustituido con arilo, ariloxi, Het2, halógeno hidroxi, estando los sustituyentes en los grupos amino, cada uno de ellos e independientemente entre sí seleccionados de entre el grupo consistente en alquilo de C1-4, arilo, arilC1-4alquilo, C3-7cicloalquilo, C3-7cicloalquilC1-4alquilo, Het1, Het2, Het1C1-4 alquilo y Het2C1-4 alquilo; R11b es hidrógeno, C3-7cicloalquilo, C2-6alquenilo, C2-6alquinilo, arilo, Het1, Het2 o alquilo de C1-4 opcionalmente sustituido con halógeno, hidroxi, C1-4alquilS(=O)t, arilo, C3-7cicloalquilo, Het1, Het2, amino opcionalmente mono- o di sustituido estando los sustituyentes, cada uno de ellos e independientemente entre si seleccionados de entre el grupo consistente en alquilo de C1-4, arilo, arilC1-4alquilo, C3-7cicloalquilo, C3-7 cicloalquilC1-4alquilo, Het1, Het2, Het1C1-4alquilo y Het2C1-4alquilo; pudiendo R11b estar ligado al resto de la molécula por intermedio de un grupo sulfonilo; cada uno de los t, independientemente entre sí, vale 0, 1 o 2; R2 es hidrógeno o alquil de C1-6; L es -C(=O)-, -O-(=O)-, -NR8-C(=O)-, -O-C1-6alcanodiil-C(=O)-, -NR8-C1-6alcanodiil-C(=O)-, -S(=O)2-, -O-S(=O)2, NR8-S(=O)2, en lo cual sea el grupo C(=O) sea el grupo S(=O)2 está fijado a la parte NR2; con lo cual la parte alcanodiilo está opcionalmente sustituido con arilo, Het1, Het2; R3 es alquilo de C1-6, arilo, C3-7cicloalquilo, C3-7cicloalquilC1-4alquilo, o arilC1-4alquilo; R4 es hidrógeno, C1-4alquiloxicarbonilo, carboxilo, aminocarbonilo, mono- o di(C1-4alquil)aminocarbonilo, C3-7cicloalquilo, C2-6 alquenilo, C2-6 alquinilo, o C1-6 alquilo opcionalmente sustituido con uno o más sustituyentes, cada uno de ellos e independientemente entre sí seleccionados de entre el grupo consistente en arilo, Het1, Het2, C3-7cicloalquilo, C1-4alquiloxicarbonilo, carboxilo, aminocarbonilo, mono- o di(C1-4alquil)aminocarbonilo, aminosulfonilo, C1-4 alquilS(=O)t, hidroxi, ciano, halógeno y amino opcionalmente mono o disustituido, estando los sustituyentes, cada uno de ellos e independientemente entre sí seleccionados de entre el grupo consistente en alquilo C1-4, arilo, arilC1-4alquilo, C3-7cicloalquilo, C3-7cicloalquilC1-4alquilo, Het1, Het2, Het1C1-4alquilo y Het2C1-4 alquilo; A es C1-6 alcanodiilo, -C(=O)-, -C(=S)-, -S(=O)2, C1-6alcanodiil-C(=O)-, C1-6alcanodiil-C(=S)- o C1-6alcanodiil-S(=O)2-; estando el punto de fijación al átomo de nitrógeno es el grupo C1-6alcanodiilo en aquellas partes que contienen dicho grupo; R5 es hidrógeno, hidroxi, alquilo de 1 a 6 átomos de carbono; Het1C1-6alquilo, Het2C1-6alquilo, aminoC1-6alquilo, pudiendo el grupo amino estar mono o disustituido con alquilo de C1-4; R6 es C1-6alquiloxi, Het1, Het1 oxi, Het2, Het2 oxi, arilo, ariloxi; y en el caso en que -A- no es C1-6alcanodiilo, entonces R6 también puede ser C1-6alquilo, Het1-C1-4 alquilo, Het1 oxiC1-4alquilo, Het2C1-4alquilo, Het2 oxiC1-4alquilo, arilC1-4alquilo, ariloxiC1-4alquilo o aminoC1-4alquilo; pudiendo cada uno de los grupos amino en la definición de R6, estar opcionalmente sustituido con uno o más sustituyentes, cada uno de ellos independientemente entre sí seleccionados de entre el grupo consistente en alquilo de C1-4, C1-4 alquilcarbonilo, C1-4alquiloxicarbonilo, arilo, arilcarbonilo, ariloxicarbonilo, Het1, Het2, arilC1-4alquilo, Het1C1-4alquilo o Het2C1-4alquilo; y -A-R6 también puede ser hidroxiC1-4alquilo; R5 y-A-R6 tomados conjuntamente con el átomo de nitrógeno al cual están unidos, pueden también formar Het1 o Het2. También se dan a conocer: composiciones farmacéuticas que comprenden dichos compuestos, un método in vitro para inhibir la replicación retroviral y el uso de dichos compuestos en la fabricación de medicamentos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01201308 | 2001-04-09 | ||
| US28770401P | 2001-05-02 | 2001-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035819A1 true AR035819A1 (es) | 2004-07-14 |
Family
ID=26076876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101301A AR035819A1 (es) | 2001-04-09 | 2002-04-09 | 2-(amino sustituido)-benzoxazol sulfonamidas, inhibidoras de la proteasa del hiv, composiciones farmaceuticas que comprenden dichos compuestos, metodo in vitro para inhibir la replicacion retroviral y uso de dichos compuestos en la fabricacion de medicamentos |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7244752B2 (es) |
| EP (1) | EP1397367A2 (es) |
| JP (1) | JP4417010B2 (es) |
| KR (1) | KR100872029B1 (es) |
| CN (1) | CN100491360C (es) |
| AP (1) | AP1544A (es) |
| AR (1) | AR035819A1 (es) |
| AU (1) | AU2002257774B2 (es) |
| BG (1) | BG66371B1 (es) |
| BR (1) | BR0208796A (es) |
| CA (1) | CA2442870C (es) |
| CZ (1) | CZ303139B6 (es) |
| EA (1) | EA007383B1 (es) |
| EE (1) | EE05384B1 (es) |
| HR (1) | HRP20030905B1 (es) |
| HU (1) | HUP0303744A3 (es) |
| IL (1) | IL158092A0 (es) |
| MX (1) | MXPA03009179A (es) |
| NO (1) | NO328896B1 (es) |
| NZ (1) | NZ528954A (es) |
| OA (1) | OA12464A (es) |
| PL (1) | PL367084A1 (es) |
| SK (1) | SK288232B6 (es) |
| WO (1) | WO2002081478A2 (es) |
| ZA (1) | ZA200307683B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100491360C (zh) * | 2001-04-09 | 2009-05-27 | 泰博特克药品有限公司 | 广谱2-(取代的-氨基)-苯并唑磺酰胺hiv蛋白酶抑制剂 |
| EE05307B1 (et) * | 2001-05-11 | 2010-06-15 | Tibotec Pharmaceuticals Ltd. | Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks |
| AU2003202914A1 (en) | 2002-01-07 | 2003-07-24 | Sequoia Pharmaceuticals | Broad spectrum inhibitors |
| US7285566B2 (en) * | 2002-01-07 | 2007-10-23 | Erickson John W | Resistance-repellent retroviral protease inhibitors |
| US7157489B2 (en) | 2002-03-12 | 2007-01-02 | The Board Of Trustees Of The University Of Illinois | HIV protease inhibitors |
| IL165043A0 (en) * | 2002-05-17 | 2005-12-18 | Tibotec Pharm Ltd | broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors |
| US7807845B2 (en) * | 2004-03-11 | 2010-10-05 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
| CA2566340C (en) * | 2004-05-07 | 2014-05-06 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
| PT1856125E (pt) | 2005-02-25 | 2009-11-06 | Tibotec Pharm Ltd | Síntese de precursor de inibidor de proteases |
| DE102010044584A1 (de) * | 2010-09-07 | 2012-03-08 | Kautex Textron Gmbh & Co. Kg | Kraftstoffbehälter aus thermoplastischem Kunststoff |
| WO2014194519A1 (en) | 2013-06-07 | 2014-12-11 | Merck Sharp & Dohme Corp. | Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3021326A1 (de) | 1980-06-06 | 1981-12-17 | Drägerwerk AG, 2400 Lübeck | Einrichtung zur messung von mindestens zwei pneumatischen lungenparametern und messverfahren hierzu |
| US4448192A (en) | 1982-03-05 | 1984-05-15 | Hewlett Packard Company | Medical ventilator device parametrically controlled for patient ventilation |
| IT1185906B (it) | 1985-09-13 | 1987-11-18 | Luciano Gattinoni | Sistema ed apparecchio biomedicale per la misurazione con precisione dei valori di variazione di pressione e volume nei polmoni di un paziente |
| DE3919840A1 (de) | 1989-06-17 | 1991-01-17 | Hoechst Ag | Verfahren zur herstellung von aromatischen sulfonsaeurechloriden |
| US5136043A (en) | 1989-06-17 | 1992-08-04 | Hoechst Aktiengesellschaft | Process for the preparation of aromatic sulfonyl chlorides |
| EP0445926B1 (en) | 1990-03-09 | 1996-08-21 | Milliken Research Corporation | Organic materials having sulfonamido linked poly(oxyalkylene) moieties and their preparation |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| PH30929A (en) | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| EP0715618B1 (en) * | 1993-08-24 | 1998-12-16 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
| PT721331E (pt) | 1993-10-01 | 2002-05-31 | Astrazeneca Ab | Processo i |
| DK0855388T3 (da) | 1993-11-23 | 2002-04-29 | Searle & Co | Fremgangsmåde til fremstilling af mellemprodukter, der kan anvendes til syntese af retrovirale proteaseinhibitorer |
| ATE382041T1 (de) | 1995-01-20 | 2008-01-15 | Searle Llc | Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen |
| US5756533A (en) * | 1995-03-10 | 1998-05-26 | G.D. Searle & Co. | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
| US5705500A (en) | 1995-03-10 | 1998-01-06 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
| CN1530372A (zh) * | 1995-03-10 | 2004-09-22 | G.D.ɪ����˾ | 杂环羰基氨基酸羟乙氨基磺酰胺逆转录病毒蛋白酶抑制剂 |
| US6150556A (en) * | 1995-03-10 | 2000-11-21 | G. D. Dearle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
| US5691372A (en) * | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
| AU7722296A (en) * | 1995-11-15 | 1997-06-05 | G.D. Searle & Co. | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
| GB9525994D0 (en) | 1995-12-20 | 1996-02-21 | Univ Manitoba | Improvements in delivery of assist modes of mechanical ventilation |
| IL124935A (en) | 1996-05-20 | 2001-06-14 | Janssen Pharmaceutica Nv | Dispersible antifungal compositions comprising itraconazole with improved bioavailability |
| EP0969821B1 (en) | 1997-03-26 | 2003-06-04 | Janssen Pharmaceutica N.V. | Pellets having a core coated with an antifungal and a polymer |
| SE513969C2 (sv) | 1997-05-17 | 2000-12-04 | Draegerwerk Ag | Anordning och förfarande för bestämning av respirationssystemetsmekaniska egenskaper |
| WO1999006254A1 (de) * | 1997-07-31 | 1999-02-11 | Continental Teves Ag & Co. Ohg | Verfahren und vorrichtung zur aktivierung einer bremsanlage |
| AU2012199A (en) | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| WO1999033792A2 (en) | 1997-12-24 | 1999-07-08 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
| BR9814484A (pt) | 1997-12-24 | 2000-10-10 | Vertex Pharma | "pró-drogas de inibidores de aspartil protease" |
| AU4828199A (en) * | 1998-06-23 | 2000-01-10 | Board Of Trustees Of The University Of Illinois, The | Multi-drug resistant retroviral protease inhibitors and associated methods |
| CA2336160C (en) | 1998-06-23 | 2015-02-17 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of compounds for treating hiv |
| ATE398623T1 (de) * | 1999-10-06 | 2008-07-15 | Tibotec Pharm Ltd | Hexahydrofuro-2,3-b furan-3-yl-n- 3-,(1,3- benzodioxol-5-ylsulfonyl)(isobutyl)amino -1- benzyl-2-hydroxypropyl carbamat als retrovirusproteasehemmer |
| CN100491360C (zh) * | 2001-04-09 | 2009-05-27 | 泰博特克药品有限公司 | 广谱2-(取代的-氨基)-苯并唑磺酰胺hiv蛋白酶抑制剂 |
-
2002
- 2002-04-09 CN CNB028114809A patent/CN100491360C/zh not_active Expired - Fee Related
- 2002-04-09 HU HU0303744A patent/HUP0303744A3/hu unknown
- 2002-04-09 EP EP02727554A patent/EP1397367A2/en not_active Withdrawn
- 2002-04-09 EE EEP200300494A patent/EE05384B1/xx not_active IP Right Cessation
- 2002-04-09 AU AU2002257774A patent/AU2002257774B2/en not_active Ceased
- 2002-04-09 HR HR20030905A patent/HRP20030905B1/xx not_active IP Right Cessation
- 2002-04-09 BR BR0208796-0A patent/BR0208796A/pt not_active IP Right Cessation
- 2002-04-09 AR ARP020101301A patent/AR035819A1/es not_active Application Discontinuation
- 2002-04-09 CZ CZ20032936A patent/CZ303139B6/cs not_active IP Right Cessation
- 2002-04-09 WO PCT/EP2002/004012 patent/WO2002081478A2/en not_active Ceased
- 2002-04-09 OA OA1200300253A patent/OA12464A/en unknown
- 2002-04-09 US US10/474,162 patent/US7244752B2/en not_active Expired - Fee Related
- 2002-04-09 CA CA2442870A patent/CA2442870C/en not_active Expired - Fee Related
- 2002-04-09 MX MXPA03009179A patent/MXPA03009179A/es active IP Right Grant
- 2002-04-09 EA EA200301110A patent/EA007383B1/ru not_active IP Right Cessation
- 2002-04-09 NZ NZ528954A patent/NZ528954A/en not_active IP Right Cessation
- 2002-04-09 AP APAP/P/2003/002882A patent/AP1544A/en active
- 2002-04-09 PL PL02367084A patent/PL367084A1/xx unknown
- 2002-04-09 JP JP2002579466A patent/JP4417010B2/ja not_active Expired - Fee Related
- 2002-04-09 SK SK1339-2003A patent/SK288232B6/sk not_active IP Right Cessation
- 2002-04-09 IL IL15809202A patent/IL158092A0/xx not_active IP Right Cessation
- 2002-04-09 KR KR1020037013144A patent/KR100872029B1/ko not_active Expired - Fee Related
-
2003
- 2003-10-01 BG BG108218A patent/BG66371B1/bg unknown
- 2003-10-01 ZA ZA2003/07683A patent/ZA200307683B/en unknown
- 2003-10-08 NO NO20034505A patent/NO328896B1/no not_active IP Right Cessation
-
2007
- 2007-01-23 US US11/626,183 patent/US7595334B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108073T1 (el) | Αναστολεις της hiv πρωτεασης ευρεως φασματος σουλφοναμιδιου 2-(υποκατεστημενο-αμινο) βενζοθειαζολης | |
| AR035819A1 (es) | 2-(amino sustituido)-benzoxazol sulfonamidas, inhibidoras de la proteasa del hiv, composiciones farmaceuticas que comprenden dichos compuestos, metodo in vitro para inhibir la replicacion retroviral y uso de dichos compuestos en la fabricacion de medicamentos | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| CY1109247T1 (el) | Αναστολεις πρωτεασης hiv σουλφοναμιδιου 2-αμινο-βενζοξαζολης ευρεως φασματος | |
| AR044518A1 (es) | Inhibidores de integrasa de hiv | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| AR047744A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico | |
| AR075005A1 (es) | Derivados de sulfonamida | |
| AR046600A1 (es) | Diazaespiroalcanos y su uso como tratamiento para enfermedades mediadas por ccr8 | |
| AR062680A1 (es) | Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas | |
| AR036106A1 (es) | Compuestos azaindoles inhibidores de quinasa selectivos, composiciones farmaceuticas y el uso de dicha composicion para la fabricacion de un medicamento | |
| AR047823A1 (es) | Derivados de 1,2,3,4-tetrahidroisoquinolina sustituida | |
| AR073450A1 (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| AR104208A1 (es) | Compuestos bicíclicos como inhibidores de autotaxina (atx) | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR046942A1 (es) | Arilpirazoles sustituidos, un procedimiento para su preparacion, composiciones farmaceuticas o veterinarias que los contienen como principio activo y su uso en la fabricacion de un medicamento parasiticida humano o animal. | |
| AR066154A1 (es) | Derivados de piperidina / piperazina | |
| AR039887A1 (es) | Inhibidores de la proteasa de hiv de benzisoxazol sulfonamida sustituida de amplio espectro, composiciones y combinaciones farmaceuticas, y uso de dichos inhibidores para la elaboracion de un medicamento para tratar condiciones asociadas con hiv y otros retrovirus patogenos | |
| AR037976A1 (es) | Sulfonamidas que contienen fenilo sustituido con grupos heterociclicos, una composicion farmaceutica, un producto combinado con un agente antirretroviral y el uso de las mismas para la fabricacion de un medicamento. | |
| AR034309A1 (es) | Derivados fenilsulfonilaminofenilamina, procedimiento para su preparacion, medicamentos y el uso de dichos derivados para la preparacion de medicamentos antivirales | |
| AR038928A1 (es) | Benzimidazol sulfonamidas sustituidas, como inhibidores de amplio espectro de la proteasa del vih | |
| AR046340A1 (es) | Derivados de piperazinilo y piperidinilo como antagonistas de receptor ccr 3. composiciones farmaceuticas. | |
| AR045117A1 (es) | Imidazo-pirimidinas y triazolo-pirimidinas:ligandos del receptor de benzodiazepina | |
| AR035866A1 (es) | 2-(amino sustituido)-benzotiazol sulfonamidas inhibidoras de proteasa de hiv de amplio espectro, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y el uso de dichos compuestos para la manufactura de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |